- Home
- SPXX vs THRD Comparison
SPXX vs THRD Comparison
Compare SPXX & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPXX
- THRD
- Stock Information
- Founded
- SPXX 2004
- THRD 2019
- Country
- SPXX United States
- THRD United States
- Employees
- SPXX N/A
- THRD N/A
- Industry
- SPXX Trusts Except Educational Religious and Charitable
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- SPXX Finance
- THRD Health Care
- Exchange
- SPXX Nasdaq
- THRD Nasdaq
- Market Cap
- SPXX 329.9M
- THRD 157.7M
- IPO Year
- SPXX N/A
- THRD 2022
- Fundamental
- Price
- SPXX $17.00
- THRD $3.45
- Analyst Decision
- SPXX
- THRD Buy
- Analyst Count
- SPXX 0
- THRD 3
- Target Price
- SPXX N/A
- THRD $14.00
- AVG Volume (30 Days)
- SPXX 51.3K
- THRD 435.5K
- Earning Date
- SPXX 01-01-0001
- THRD 03-25-2025
- Dividend Yield
- SPXX 7.55%
- THRD N/A
- EPS Growth
- SPXX N/A
- THRD N/A
- EPS
- SPXX N/A
- THRD N/A
- Revenue
- SPXX N/A
- THRD N/A
- Revenue This Year
- SPXX N/A
- THRD N/A
- Revenue Next Year
- SPXX N/A
- THRD N/A
- P/E Ratio
- SPXX N/A
- THRD N/A
- Revenue Growth
- SPXX N/A
- THRD N/A
- 52 Week Low
- SPXX $13.57
- THRD $3.18
- 52 Week High
- SPXX $16.05
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- SPXX 27.28
- THRD 30.03
- Support Level
- SPXX $16.97
- THRD $3.36
- Resistance Level
- SPXX $17.41
- THRD $3.65
- Average True Range (ATR)
- SPXX 0.30
- THRD 0.14
- MACD
- SPXX -0.15
- THRD 0.16
- Stochastic Oscillator
- SPXX 1.61
- THRD 35.48
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.